Biobanking Market Size Trends Analysis and Forecast till 2034
The global biobanking market was valued at USD 87.75 billion in 2024 and is projected to hit around USD 213.53 billion by 2034, growing at a CAGR of 9.3% during the forecast period 2025 to 2034. The growth of the market is attributed to the increasing R&D spending, expanding biobanking networks, and ongoing advancements in sample collection and processing technologies.
Biobanking Market Key Takeaways
- By region, Europe held the largest share of the biobanking market in 2024.
- By region, Asia Pacific is expected to experience the fastest growth between 2025 and 2034.
- By product, the biobanking equipment segment dominated the market in 2024.
- By product, the laboratory information management systems segment is expected to grow at the fastest CAGR over the projection period.
- By service, the biobanking & repository segment led the market in 2024.
- By service, the lab processing segment is likely to grow at a significant rate in the upcoming period.
- By biospecimen type, the human tissues segment dominated the market with the largest share in 2024.
- By biospecimen type, the stem cells segment is expected to expand at the highest CAGR during the forecast period.
- By biobank type, the physical/real biobanks segment contributed the major market share in 2024.
- By biobank type, the virtual biobanks segment is expected to expand at the fastest CAGR in the upcoming period.
- By application, the therapeutics segment dominated the market in 2024.
- By application, the clinical diagnostics segment is expected to experience significant growth between 2025 and 2034.
- By end-use, the pharmaceutical & biotechnology companies segment contributed the largest market share in 2024.
- By end-use, the CROs & CMOs segment is expected to experience the fastest growth throughout the forecast period.
How is AI Revolutionizing the Biobanking Market?
Artificial intelligence (AI) is transforming the biobanking market by enhancing the way biological data is analyzed, managed, and utilized for research and clinical applications. AI-driven tools enable faster identification of patterns and biomarkers from vast datasets, accelerating discoveries in areas like genomics, personalized medicine, and disease prediction. In biobank operations, AI improves sample tracking, quality control, and data integration, making biobanks more efficient and scalable. It also supports virtual cohort creation and advanced analytics without compromising data privacy, especially in federated systems. As AI continues to evolve, it opens new opportunities for deeper insights from biobanked samples, driving innovation across biomedical research and healthcare.
Market Overview
The biobanking market involves the collection, processing, storage, and distribution of biological samples, such as blood, tissues, and DNA, along with related health data for research and clinical use. Biobanks play a crucial role in advancing medical research, supporting drug discovery, personalized medicine, disease prevention, and public health initiatives. Their benefits include enabling long-term studies, facilitating early disease detection, and improving therapeutic targeting through access to high-quality, diverse biological data. The market is experiencing significant growth due to the rising prevalence of chronic and genetic diseases, increasing investment in precision medicine, and advancements in genomics and data analytics. Additionally, expanding collaborations between academic, clinical, and commercial entities continue to strengthen the global biobanking infrastructure.
Major Market Trends
- Rise of Population-Based and Disease-Specific Biobanks: Biobanks are increasingly being tailored to focus on specific diseases like cancer or rare disorders, or to represent diverse populations. This helps improve the relevance of samples for targeted research and ensures more inclusive healthcare innovations.
- Shift Toward Federated and Virtual Biobanking Models: Federated biobanks allow data to be analyzed across institutions without physically transferring it, maintaining privacy and compliance with data protection laws. This model supports large-scale collaboration and global research efforts.
- Increasing Public-Private Partnerships and Global Collaborations: Governments, academic institutions, and biotech companies are partnering to fund and expand biobank infrastructure. These collaborations drive innovation, standardization, and accessibility, making biobanking a key enabler of precision medicine worldwide.
Report Scope of Biobanking Market
Market Dynamics
Drivers
Increasing Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular disorders, and neurodegenerative conditions is a major driver of growth in the biobanking market. These diseases require long-term research to understand their complex biology, identify biomarkers, and develop targeted therapies, all of which depend on access to high-quality biological samples and associated data. Biobanks provide a centralized, standardized resource for researchers to study disease progression, patient responses, and genetic predispositions. As healthcare systems shift toward personalized and preventive care, the demand for biobanked specimens continues to grow. This trend is further reinforced by increasing global investments in translational research and precision medicine.
- In June 2025, Limerick launched its first cancer biobank through a joint initiative by the University of Limerick and University Hospital Limerick. The biobank enables patients to contribute tissue samples, accelerating cancer research and clinical trials. It serves as a collaborative platform linking hospital care with academic research to advance diagnostics and therapies.
Expansion of Biobanking Networks
The expansion of biobanking networks further drives the growth of the biobanking market, as it enhances accessibility, collaboration, and data sharing across institutions and borders. Larger, connected networks allow researchers to access more diverse and high-quality biospecimens, supporting robust, large-scale studies and improving the validity of research outcomes. These networks also promote standardization in sample collection, storage, and data management, ensuring consistency and reliability. Furthermore, global collaborations between hospitals, research institutes, and biotech firms foster innovation in disease understanding, drug development, and precision medicine. As these networks grow, they significantly increase the value and utility of biobanks in advancing healthcare and scientific discovery.
Restraint
What Factors are Constraining the Full Potential of the Biobanking Market?
The growth of the market is significantly restrained by several key challenges. High operational and maintenance costs, including expenses for infrastructure, storage equipment, skilled personnel, and long-term sample preservation, make it difficult for many institutions, especially in low- and middle-income countries, to establish and sustain biobanks. Ethical and legal concerns around data privacy, patient consent, and the secure use of sensitive genetic and clinical information further complicate operations, often leading to regulatory hurdles and public mistrust. These issues are particularly critical as biobanks handle increasingly large and complex datasets.
Additionally, the lack of standardized protocols for sample collection, processing, and data annotation creates inconsistencies across biobanks, limiting the comparability and interoperability of datasets. This fragmentation reduces the efficiency of research collaborations and slows the integration of biobanking into clinical and research workflows. Addressing these restraints is crucial to fully realizing the potential of biobanking in advancing global health and personalized medicine.
Opportunities
Development of Advanced Technologies
The development of advanced technologies creates significant opportunities in the biobanking market by improving the efficiency, scalability, and quality of biospecimen collection and analysis. Innovations such as automated sample storage systems, cloud-based data management, AI-driven analytics, and next-generation sequencing enable faster and more accurate research outcomes. These technologies also support real-time data sharing and integration across biobanks, enhancing collaboration and global research capabilities. Additionally, advancements in cryopreservation and biospecimen tracking ensure better sample integrity and long-term usability.
Increasing Biomedical Research
The increasing focus on biomedical research is creating new opportunities in the market by driving demand for diverse, high-quality biological samples essential for understanding diseases and developing new treatments. As biomedical research expands into areas like genomics, personalized medicine, and regenerative therapies, biobanks become crucial resources for providing well-characterized specimens linked with clinical data. This further encourages the development of advanced biobanking infrastructure and fosters collaborations between research institutions, hospitals, and biotech companies. Additionally, increased funding and initiatives targeting complex diseases further stimulate biobank utilization, accelerating scientific discoveries and innovation.
- In November 2024, Columbia University’s Irving Medical Center launched the BRIDGE facility, a centralized biobank to store up to 12 million patient samples. Unlike previous disease-specific collections, BRIDGE offers broad access to diverse biospecimens. This resource aims to accelerate medical research by providing researchers with valuable samples across various conditions.
Segment Outlook
By Product
What Made Biobanking Equipment the Dominant Segment in the Biobanking Market in 2024?
The biobanking equipment segment dominated the market in 2024 due to the heightened demand for advanced and reliable storage solutions to preserve biological samples under optimal conditions. High-quality equipment such as ultra-low temperature freezers, automated storage systems, and cryogenic storage devices are critical for maintaining sample integrity and ensuring long-term viability. Increasing investments in research and development, along with the rising adoption of automation to enhance efficiency and reduce human error, further boosted this segment. Additionally, stringent regulatory standards for sample storage and handling have driven the need for sophisticated equipment, solidifying its dominant position in the market.
The laboratory information management systems (LIMS) segment is expected to expand at the fastest rate during the forecast period due to the increasing need for efficient data management and sample tracking. As biobanks handle vast amounts of biological specimens and associated data, LIMS provide critical solutions for organizing, storing, and retrieving information with accuracy and security. The growing adoption of automation and digitalization in biobanking workflows further drives demand for advanced LIMS platforms. Additionally, regulatory compliance and data integrity requirements are pushing biobanks to implement robust information management systems, fueling the rapid growth of this segment.
By Service
How Does the Biobanking & Repository Segment Lead the Biobanking Market in 2024?
The biobanking & repository segment led the market in 2024 due to the growing need for organized storage, management, and distribution of biological samples for research and clinical use. Increasing demand for high-quality biospecimens in drug development, personalized medicine, and disease research has driven the expansion of biobanking services. These services ensure proper sample cataloging, data management, and compliance with regulatory standards, which are critical for reliable research outcomes. Moreover, collaborations between biobanks and pharmaceutical companies have further fueled the growth of this segment by supporting large-scale clinical trials and translational research.
The lab processing segment is expected to experience significant growth in the coming years, driven by the increasing demand for high-quality sample preparation and analysis services. As biobanks expand their collections, efficient processing of biological specimens, including extraction, purification, and characterization, is critical for ensuring sample integrity and usability in research. Advances in automation and standardized protocols are improving throughput and accuracy, making lab processing services more essential. Additionally, the rising focus on personalized medicine and translational research drives the need for precise and reliable sample processing, fueling growth in this segment.
By Biospecimen Type
Why Did the Human Tissues Segment Dominate the Biobanking Market in 2024?
The human tissues segment dominated the biobanking market in 2024. This is mainly due to the increased demand for tissue samples in research related to cancer, regenerative medicine, and genetic disorders. Human tissues provide critical insights into disease mechanisms and treatment responses, making them invaluable for developing targeted therapies and personalized medicine. Advances in tissue preservation and processing technologies have improved sample quality and usability, further driving demand. Additionally, growing investments in biobanking infrastructure and collaborations with healthcare institutions have supported the widespread collection and storage of human tissues, solidifying this segment’s leading position.
The stem cells segment is expected to grow at the fastest CAGR during the projection period. This is mainly due to the increasing use of stem cells in regenerative medicine and advanced therapeutic research. Stem cells hold significant potential for treating a wide range of diseases, including neurodegenerative disorders, cancers, and autoimmune conditions, driving demand for their preservation. Additionally, advancements in stem cell technologies and growing investments in stem cell-based therapies are fueling the need for specialized biobanking services. The ability to store and access high-quality stem cell samples is critical for both clinical applications and research, making this segment a rapidly expanding area within biobanking.
By Biobank Type
How Does the Physical/Real Biobanks Contribute the Major Market Share in 2024?
The physical/real biobanks segment dominated the biobanking market while holding the largest share in 2024 due to their established infrastructure for securely storing and managing large volumes of biological samples. These biobanks provide controlled environments with advanced preservation technologies, ensuring sample integrity and long-term viability critical for research and clinical applications. The rising demand for well-maintained biospecimens in drug discovery, diagnostics, and personalized medicine has reinforced the importance of physical biobanks. Moreover, stringent regulatory requirements for sample storage and handling have made physical biobanks the preferred choice for compliance and quality assurance, driving their market dominance.
The virtual biobanks segment is expected to expand at the fastest CAGR throughout the forecast period due to the increasing demand for digital data management and remote access to biospecimen information. Virtual biobanks enable efficient sharing of data across multiple institutions without the need for physical sample transfer, reducing costs and logistical challenges. Advances in cloud computing, data security, and bioinformatics are enhancing the capabilities and appeal of virtual biobanks. Additionally, the rise of collaborative research and the need for large datasets to support precision medicine are driving adoption, making virtual biobanks crucial.
By Application
Why Did the Therapeutics Segment Dominate the Biobanking Market in 2024?
The therapeutics segment dominated the market in 2024 due to the increased reliance on high-quality biological samples for drug development and personalized medicine. Biobanks provide critical access to diverse biospecimens that enable researchers to identify biomarkers, understand disease mechanisms, and test new therapies effectively. The rise of precision medicine and targeted therapies has further accelerated the demand for well-characterized samples to tailor treatments to individual patients.
The clinical diagnostics segment is expected to grow at a significant rate in the coming years, owing to the rising demand for accurate and early disease detection. Biobanks provide critical biological samples that enable the development and validation of advanced diagnostic tests, improving patient outcomes. Increasing prevalence of chronic diseases and personalized medicine approaches further drive the need for reliable diagnostic tools supported by high-quality biobank samples. Additionally, technological advancements in molecular diagnostics and genomics are expanding the applications of biobanking in clinical diagnostics, fueling segmental growth.
By End-Use
How Does Pharmaceutical & Biotechnology Companies Contribute the Largest Market Share in 2024?
The pharmaceutical & biotechnology companies segment held the largest share of the biobanking market in 2024. This is mainly due to their extensive involvement in drug discovery, development, and personalized medicine. These companies rely heavily on access to diverse and well-characterized biological samples to identify new drug targets, validate biomarkers, and conduct preclinical and clinical research. Increasing investments in biobanking collaborations and partnerships have further strengthened their ability to accelerate therapeutic development. Moreover, the growing focus on precision medicine and advanced therapies has heightened the demand for high-quality biospecimens, positioning pharmaceutical and biotech firms as the largest end-users in the market.
The CROs & CMOs segment is expected to expand at the fastest rate throughout the projection period. This is primarily due to the increasing outsourcing of research and development activities by pharmaceutical and biotechnology companies. These organizations rely on CROs and CMOs for efficient sample management, processing, and storage, which helps accelerate drug development timelines. The rising complexity of clinical trials and the demand for high-quality, well-characterized biospecimens further drive the need for specialized biobanking services offered by CROs and CMOs. Additionally, their expertise in regulatory compliance and advanced technologies makes them preferred partners, boosting growth in this segment.
Regional Insights
What Made Europe the Dominant Region in the Biobanking Market?
Europe registered dominance in the biobanking market by capturing the largest share in 2024. This is mainly due to its well-established infrastructure, strong government support, and extensive network of biorepositories. The region has been at the forefront of biomedical research, with major initiatives like BBMRI-ERIC (Biobanking and BioMolecular resources Research Infrastructure) facilitating collaboration across countries. High investment in healthcare innovation, personalized medicine, and genomics research has further strengthened biobanking activities. Additionally, strict regulatory frameworks and ethical standards have fostered public trust and participation in biobanking programs.
Germany is a major contributor to the European biobanking market, driven by its advanced healthcare infrastructure, strong research institutions, and significant government and private sector investment in biomedical research. The country hosts several large-scale biobanks and is actively involved in European initiatives like BBMRI-ERIC. Germany’s focus on precision medicine, genomics, and biotechnology supports the collection and use of high-quality biospecimens. Its regulatory compliance and emphasis on data security further enhance its leadership role in the region’s biobanking landscape.
What Makes Asia Pacific the Fastest-Growing Market?
Asia Pacific is expected to experience the fastest growth in the coming years due to expanding healthcare infrastructure, rising investments in biomedical research, and rising government support for precision medicine and genomics. Countries like China, India, and Japan are significantly increasing their focus on life sciences and clinical research, driving the demand for biobanking services. Additionally, the region’s large and genetically diverse population offers valuable opportunities for disease research and drug development. Increasing awareness about the importance of biobanks in personalized medicine and the rising prevalence of chronic diseases further accelerate market growth. Collaborations between international organizations and regional institutions are also helping build biobanking capacity and standards across Asia Pacific.
China is leading the charge in the Asia Pacific biobanking market due to the rapid expansion of biotechnology sector, strong government support, and large-scale investments in healthcare research. The country has established numerous national and regional biobanks, supported by strategic initiatives to promote precision medicine and genomic studies. China’s large population and genetic diversity make it a key hub for disease research and personalized therapy development.
India is emerging as a key player in the biobanking market in Asia Pacific due to its large and genetically diverse population, expanding healthcare infrastructure, and growing focus on biomedical research. Government-led initiatives, such as the Indian Council of Medical Research (ICMR) biobanks and collaborations with global consortia, are facilitating standardized collection and storage of biospecimens for research into cancer, infectious diseases, and rare genetic disorders. India’s increasing investments in precision medicine and digital health technologies further support biobank-driven innovation.
- In July 2025, Union Minister Dr. Jitendra Singh inaugurated the Phenome India “National Biobank” at CSIR-IGIB, New Delhi, a major step toward building India’s own longitudinal health database. The biobank will collect genomic, lifestyle, and clinical data from 10,000 diverse individuals across the country to support personalized treatments. Modeled after the UK Biobank, it aims to enhance early diagnosis and targeted therapies for complex diseases like cancer, diabetes, and rare disorders.
Region-Wise Growth Overview of the Biobanking Market:
Biobanking Market Value Chain Analysis
1. Sample Acquisition & Collection
This stage involves sourcing and obtaining biospecimens (e.g., tissues, blood, stem cells) from donors and research subjects, along with collecting associated metadata. Institutions like the Coriell Institute for Medical Research and large national repositories such as the UK Biobank lead in cultivating well-characterized specimen collections.
2. Preservation & Storage
Specimens must be preserved under optimal conditions, cryogenic, ambient, or otherwise, to ensure long-term viability. Thermo Fisher Scientific (via Fisher BioServices), BD (Becton, Dickinson & Co.), Merck KGaA, and Biomatrica stand out with advanced storage solutions, cold chain technologies, and ambient preservation innovations.
3. Lab Processing & Sample Management
At this stage, samples undergo processing steps such as aliquoting, extraction, purification, and quality control. Providers like Hamilton Company, Tecan, and Cryoport supply automation, liquid handling systems, and logistics services that ensure high-throughput, accurate, and consistent specimen handling.
4. Data Management & Informatics
Management of sample metadata, tracking, and analytics is critical. Solutions from Thermo Fisher (LIMS), Tecan, AstridBio, and digital platforms from Qiagen power efficient sample inventory, integration with research informatics, and quality assurance workflows.
5. Distribution & Access
This stage encompasses facilitating access to biobank specimens and ensuring secure, compliant transfer to researchers or industry partners. Organizations such as BioIVT, Novogene, and the Coriell Institute provide curated, high-quality sample collections, enabling diverse applications from rare disease studies to translational research.
6. Analytics & Value-Added Services
Beyond storage, many biobanks now offer analytical services including assay development, biomarker discovery, and genomic profiling. Companies like Novogene and Qiagen enhance research value by coupling specimen management with sequencing and molecular analysis capabilities.
Key Companies Operating in the Biobanking Market
The company offers comprehensive biobanking solutions, including cryogenic storage systems, automated sample handling platforms, and LIMS. Its broad portfolio and global presence make it a one-stop provider for preservation, management, and analytics.
It provides essential consumables such as cryopreservation reagents, cell culture media, and sample-safe consumables. With a strong European footprint, it supports biobanks’ foundational needs for quality and compliance.
Qiagen supplies advanced sample preparation and automation systems, like QIAsymphony and QIAcube, tailored for genomic and molecular biobanking workflows. These solutions streamline sample processing and integrate well with research needs.
- Becton, Dickinson and Company (BD)
BD focuses on sample collection and preservation with products like blood collection tubes, cryovials, and integrated diagnostic tools. Their automation and digital tracking help enhance sample integrity and laboratory efficiency.
The company specializes in energy-efficient, ultra-low-temperature freezers and cold storage systems. Its sustainable biobanking solutions are especially valued in regions emphasizing green technology and cost-effective long-term storage.
Hamilton provides automated liquid handling systems (e.g., Microlab STAR, easyBlood) and high-throughput storage solutions like BiOS, crucial for large-scale biobanks. For instance, their automation is powering the All of Us Research Program Biobank, designed to manage over 35 million biospecimens for precision medicine research.
BioLife Solutions strengthens the biobanking ecosystem by delivering high-performance preservation media, secure storage infrastructure, and smart logistics, all essential for ensuring the integrity, accessibility, and reliability of valuable biospecimens in research and therapy development.
Novogene empowers the biobanking ecosystem by enhancing sample value with rich genomic data, delivering robust automation and quality, and providing global, scalable sequencing infrastructure, thereby advancing research outcomes and enabling precision medicine efforts.
It provides comprehensive biobanking services, including standardized sample collection and advanced management systems, which support high-quality, accessible biospecimens for research. Additionally, through collaborations with major research institutions and specialized biobanks, Coriell enhances scientific discovery and drives innovation across various fields such as genetics, cancer, and stem cell research.
Recent Developments
- In July 2025, the International Seabed Authority (ISA) launched the Deep-Sea Biobank Initiative (DBI) to improve access to deep-sea biological samples and genetic data from areas beyond national jurisdiction. Announced at the UN Ocean Conference, the DBI aims to foster inclusive research and collaboration, especially benefiting developing States. It will create a global repository of samples and establish standardized procedures for sampling, processing, and data sharing to enhance quality and accessibility.
- In June 2025, Mayo Clinic researchers developed a biobank of human salivary gland organoids from 208 donors to advance regenerative therapies for chronic dry mouth. This unique collection overcomes limited access to standardized salivary samples, supporting the discovery of biomarkers and rare regenerative cells to help restore saliva production, particularly in cases caused by radiation.
- In February 2025, India’s first retina biobank has been launched at Amrita Hospital, Kochi, marking a major step in ophthalmic research. The facility stores aqueous and vitreous samples at -70°C, supporting advanced genetic and biological studies of complex eye diseases.
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the biobanking market.
By Product
-
- Temperature Control Systems
-
-
- Freezers & Refrigerators
- Cryogenic Storage Systems
- Thawing Equipment
-
- Incubators & Centrifuges
- Alarms & Monitoring Systems
- Accessories & Other Equipment
- Biobanking Consumables
- Laboratory Information Management Systems
By Service
- Biobanking & Repository
- Lab Processing
- Qualification/ Validation
- Cold Chain Logistics
- Other Services
By Biospecimen Type
- Human Tissues
- Human Organs
- Stem Cells
-
- Adult Stem Cells
- Embryonic Stem Cells
- IPS Cells
- Other Stem Cells
- Other Biospecimens
By Biobanks Type
-
- Tissue Biobanks
- Population Based Biobanks
- Genetic (DNA/RNA)
- Disease Based Biobanks
By Application
- Therapeutics
- Drug Discovery & Clinical Research
- Clinical Diagnostics
- Other Applications
By End-use
- Pharmaceutical & Biotechnology Companies
- CROs & CMOs
- Academic & Research Institutes
- Hospitals
By Regional
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
Request Customization
Get a Sample
Get a Sample
Request Customization